A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations
Publications
This is some text inside of a div block.
October 19, 2025
Related announcements
Iambic Therapeutics to present at the 44th annual J.P. Morgan healthcare conference
